People · Operator

Christine M. Copple

Named in public records as an officer, director or promoter · active 2015–2015 · Biotechnology

1
Companies
1
Filings
$15.6M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Therabron Therapeutics, Inc.BiotechnologySeries A$15.6M$84.1M2015
Operator network

Christine M. Copple at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Vinzenz Ploerer · 4 companies · 1 sharedVinzenz PloererChristine Copple · 2 companies · 1 sharedChristine CoppleThomas M. Miller · 2 companies · 1 sharedThomas M. MillerAprile L. Pilon-Clayton · 1 companies · 1 sharedAprile L. Pilon-C…Aprile Pilon-Clayton · 1 companies · 1 sharedAprile Pilon-Clay…Blanche Johnson · 1 companies · 1 sharedBlanche JohnsonBlanche M. Johnson · 1 companies · 1 sharedBlanche M. JohnsonEric M Richman · 1 companies · 1 sharedEric M RichmanJeffrey M. Zell · 1 companies · 1 sharedJeffrey M. ZellJeffrey Zell · 1 companies · 1 sharedJeffrey ZellLinda M Chang · 1 companies · 1 sharedLinda M ChangTodd M Brady · 1 companies · 1 sharedTodd M BradyVinzenz M. Ploerer · 1 companies · 1 sharedVinzenz M. PloererTherabron Therapeutics, Inc. · $15.6M raisedTherabron Therapeutic…Christine M. CoppleCC
Christine M. Copple Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Christine M. Copple on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Vinzenz Ploerer14
Thomas M. Miller12
Christine Copple12
Jeffrey M. Zell11
Vinzenz M. Ploerer11
Aprile L. Pilon-Clayton11
Blanche M. Johnson11
Todd M Brady11
Eric M Richman11
Jeffrey Zell11
Linda M Chang11
Blanche Johnson11
Aprile Pilon-Clayton11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.